CoGenesis® BRCA-Pro
29-gene hereditary breast and ovarian cancer test
CoGenesis® BRCA-Pro looks at 29 genes linked to hereditary breast and ovarian cancers, including well‑known genes such as BRCA1, BRCA2, ATM, TP53, CHEK2, PTEN, CDH1, STK11, PALB2, RAD51C, and RAD51D. By identifying both hereditary cancer-related genetic changes, it helps you understand your lifetime risk of developing these cancers. Importantly, results may guide clinical decisions: for example, people with BRCA1/2 mutations may benefit from targeted treatments such as PARP inhibitors (PARPi).
- Assessing inherited risk for breast and ovarian cancers
- Identifying carriers of pathogenic variants in BRCA1/2 and related genes
- Informing clinical management, including surveillance, preventive strategies, and potential eligibility for PARP inhibitor therapy
- Not intended as a diagnostic test for active cancer.
- Detecting non‑genetic or environmental causes of cancer
- Predicting exact age of onset or severity of disease
- Serving as a stand‑alone diagnostic tool without clinical correlation
| Step / Test | Accuracy | Notes |
|---|---|---|
| Variant calling – SNP | >99.9% | |
| Variant calling – Indel | >99% |
4mL Peripheral blood (EDTA), 2mL saliva, or buccal swab
Preferred sample type:
- 4mL Blood (EDTA tube),
- Codex-provided buccal swabs (4 swabs)
- Codex-provided saliva collection kit (2mL)
Saliva or buccal swab sample collection: Follow the enclosed instructions; do not eat, drink, or smoke for 30 minutes before collection.
- Insufficient DNA quantity or poor DNA quality
- Improperly labeled or contaminated samples
- Degraded specimens due to incorrect storage or transport
- Non-human samples or inappropriate specimen types
Samples must be collected and submitted by a licensed healthcare professional.
- Keep Blood samples at 4–8°C after collection; avoid freezing, deliver within 48 hours of collection.
- Saliva or buccal swabs are stability in room temperature for up to 7 days. Address: Unit 220, 2/F, Building 16W, HKSTP, Pak Shek Kok, NT, Hong Kong. Tel: +852 3008 2560
- Results may identify pathogenic, likely pathogenic, or variants of uncertain significance (VUS).
- Positive findings can inform risk‑reducing strategies and treatment options.
- Genetic counseling is recommended to help families understand implications.
Hereditary breast and ovarian cancers are often linked to mutations in BRCA1/2 and other DNA repair genes. About 5–10% of breast cancers are hereditary, and about 10–15% of ovarian cancers are hereditary. If you have a breast cancer gene mutation, your chance of getting breast cancer is 10 times higher than the general population. Identifying these mutations provides actionable insights: carriers may consider enhanced screening, preventive surgery, or targeted therapies. Early detection and prevention can reduce the risk of breast cancer by 90% and ovarian cancer by 85%. PARP inhibitors (PARPi) are an important treatment option for patients with BRCA‑related cancers.
— Manahan, E. et al. Ann Surg Oncol, 26,10 (2019)Genetic testing should be made available to all newly diagnosed breast cancer patients.
— Konstantinopoulos PA et al. J Clin Oncol, 38,11 (2020)All women diagnosed with epithelial ovarian cancer should have germline genetic testing for BRCA1/2.
Hong Kong-based molecular diagnostics laboratory specialising in clinical genomics, precision oncology, and rare disease diagnosis. Accredited to ISO 27001 and GenQA standards.
© 2026 Codex Genetics Limited. All rights reserved.
